Dr. Reuben Mari Valenzuela, MD

Dr. Valenzuela practices at Springfield Clinic Urgent Care - Main in Springfield, Illinois.

Dr. Valenzuela's NPI, 1922328103, was assigned on June 10, 2010. Dr. Valenzuela holds Illinois license 036141397.

Dr. Valenzuela's primary practice is Springfield Clinic Urgent Care - Main, at 1025 S 6th St, Springfield, IL 62703. The practice phone is (217) 528-7541.

Dr. Valenzuela's primary practice is Springfield Clinic Urgent Care - Main in Springfield, Illinois. Dr. Valenzuela is also affiliated with Springfield Memorial Hospital. The medical group on file is Springfield Clinic. Dmand AI also links Dr. Valenzuela to 4 more hospitals and 1 group practice or clinic, each named with a free account. Dr. Valenzuela's employer is on file too: an urgent care center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Valenzuela practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Valenzuela's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Valenzuela's licenses on file in 2 states: Illinois and Utah.

CMS data shows 1,234 Medicare services from Dr. Valenzuela across 7 procedure codes in 2024, for 324 Medicare patients. Medicare paid $61,448 for them. Every service was in an office.

CMS counts 324 Medicare patients who saw Dr. Valenzuela in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Valenzuela's median patient age at 56, with 69% women.

In 2024, Dr. Valenzuela wrote 2,307 Medicare Part D claims for 332 patients. 79% of them were for generic drugs. CMS names the drug for 2,044 of them, across 53 drugs with 11 or more claims each, at $3,548,684 in total drug cost. In 2023, CMS named 1,493 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Valenzuela for performance year 2024, reported through an alternative payment model (APM). Dr. Valenzuela accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Valenzuela as offering telehealth.

Dmand AI links 10 papers to Dr. Valenzuela, published from 2012 to 2019. 2016 was the busiest year, with 3. The most frequent topics are Multiple Sclerosis, Immunosuppressive Agents and Cytokines. Dr. Valenzuela has published most often in J Neuroimmunol. Dr. Valenzuela's most frequent co-authors are Kathleen B. Digre, MD, Jorge C. Kattah and John H. Pula, MD.

Dmand AI links Dr. Valenzuela to 3 clinical trials. Conditions studied include Multiple Sclerosis and Demyelinating Autoimmune Diseases, CNS. EMD Serono Research & Development Institute, Inc. sponsors the most, 2.

CMS Open Payments shows 1,475 general payments to Dr. Valenzuela from 51 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Biogen, Inc. paid the most, $149,127.